Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Neuroimmunological mechanisms of chronic pain syndrome

https://doi.org/10.14412/2074-2711-2016-2-113-116

Full Text:

Abstract

The article considers the mechanisms of chronic low back pain. Three pathophysiological mechanisms: nociceptive, neurogenic (neuropathic), and psychogenic are noted to be involved in the development of pain syndrome. The role of cellular and molecular changes in the posterior horn and in the somatosensory dysregulated mechanism of neuropathic pain is shown. Immunological processes, including neurohumoral (serotoninergic) and hormonal (sex hormones and specific proteins) ones, play an important role in the development of pain. The generalization and further study of these mechanisms are embodied in approaches to therapy for pain syndromes and hence these require analysis and further investigation. 

About the Authors

I. A. Vyshlova
Stavropol State Medical University, Ministry of Health of Russia, Stavropol
Russian Federation

Department of Neurology, Neurosurgery and Medical Genetics

310, Mir Street, Stavropol 355017 



S. M. Karpov
Stavropol State Medical University, Ministry of Health of Russia, Stavropol
Russian Federation

Department of Neurology, Neurosurgery and Medical Genetics

310, Mir Street, Stavropol 355017 



A. I. Starodubtsev
Stavropol State Medical University, Ministry of Health of Russia, Stavropol
Russian Federation

Department of Neurology, Neurosurgery and Medical Genetics

310, Mir Street, Stavropol 355017 



References

1. Кукушкин МЛ, Хитров НК. Общая патология боли. Москва: Медицина; 2004. 144 с. [Kukushkin ML, Khitrov NK. Obshchaya patologiya boli [General pathology of pain]. Moscow: Meditsina; 2004. 144 p.]

2. Merskey H, Bogduk N, editors. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms prepared by International Association for the Study of Pain, Task Force on Taxonomy. 2nd ed. Seattle: IASPPress; 1994. 222 p.

3. McMahon SB, Koltzenburg M, editors. Wall and Melzack's Textbook of Pain. 5th ed. Elsevier Churchill Livingstone; 2005. 1239 p.

4. Wang XJ, Ye M, Zhang YH, Chen SD. CD200-CD200R regulation of microglia activation in the pathogenesis of Parkinson's disease. J Neuroimmune Pharmacol. 2007 Sep;2(3): 259-64. Epub 2007 May 18.

5. Кукушкин МЛ. Механизмы развития и принципы этиопатогенетической терапии хронической боли. Журнал неврологии и психиатрии им. С.С. Корсакова. 2012:(2);89- 94. [Kukushkin ML. Mechanisms of development and principles of etiopathogenetic therapy of chronic pain. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2012:(2);89-94. (In Russ.)].

6. Milligan ED, Twining C, Chacur M, et al. Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J Neurosci. 2003 Feb 1;23(3):1026-40. DOI:10.1186/1744-8069-4-65

7. Yamamoto Y, Terayama R, Kishimoto N, et al. Activated microglia contribute to convergent nociceptive inputs to spinal dorsal horn neurons and the development of neuropathic pain. Neurochem Res. 2015 May;40(5):1000-12. doi: 10.1007/s11064-015-1555-8. Epub 2015 Mar 18.

8. Gao YJ, Ji RR. Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. Pharmacol Ther. 2010 Apr;126(1):56-68. doi: 10.1016/j.pharmthera. 2010.01.002. Epub 2010 Feb 1.

9. Moalem G, Tracey DJ. Immune and inflammatory mechanisms in neuropathic pain. Brain Res Rev. 2006 Aug;51(2):240-64. Epub 2006 Jan 4.

10. Mense S. Peripheral and central mechanisms of musculoskeletal pain. Pain. 2008, an updated review. Seattle: IASP Press; 2008. P. 55-62.

11. Treede RD, Jensen TS, Campbell GN, et al. Neuropathic pain: redefinition and a grading system for clinical and research diagnostic purposes. Neurology. 2008 Apr 29;70(18):1630-5. Epub 2007 Nov 14.

12. Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron. 2006 Oct 5;52(1): 77-92.

13. Подчуфарова ЕВ, Яхно НН. Боль в спине. Москва: ГЭОТАР-Медиа; 2013. 368 с. [Podchufarova EV, Yakhno NN. Bol' v spine [Back pain]. Moscow: GEOTAR-Media; 2013. 368 p.]

14. Kraemer J. Intervertebral disk diseases causes, diagnosis, treatment, and prophylaxis. 2 nd ed. New York: Thieme medical publishers; 1990.

15. Вознесенская ТГ, Вейн АМ. Головная боль напряжения. Consilium medicum. 1999;(2):63-6. [Voznesenskaya TG, Vein AM. Tension-type headache. Consilium medicum. 1999;(2):63-6. (In Russ.)].

16. Fischer J. Schmerztherapie mit Lokalanä sthetika. Thieme; 2000. 192 p.

17. Парфенов ВА. Причины, диагностика и лечение боли в нижней части спины. Нев- рология, нейропсихиатрия, психосоматика. 2009;1(1):19-22. [Parfenov VA. Low back pain: causes, diagnosis, and treatment. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2009;1(1): 19-22. (In Russ.)]. DOI: http://dx.doi.org/10. 14412/2074-2711-2009-17

18. Крыжановский ГН, редактор. Дизрегуляционная патология. Москва: Медицина; 2002. 632 с. [Kryzhanovskii GN, editor. Dizregulyatsionnaya patologiya [Disregulation disease]. Moscow: Meditsina; 2002. 632 p.]

19. Данилов АБ, Давыдов ОС. Нейропатическая боль. Москва: Боргес; 2007. 192 с. [Danilov AB, Davydov OS. Neiropaticheskaya bol' [Neuropathic pain]. Moscow: Borges; 2007. 192 p.]

20. Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006 Nov;13(11):1153-69. DOI: 10.1111/j.1468- 1331.2010.02999.x.

21. Пшенникова МГ, Смирнова ВС, Графова ВН и др. Устойчивость к развитию невропатического болевого синдрома у крыс линии август и популяции вистар, обладающих разной врожденной устойчивостью к стрессовому воздействию. Боль. 2008:(2);13-6. [Pshennikova MG, Smirnova VS, Grafova VN, et al. Resistance to the development of neuropathic pain syndrome in rats of August line and Wistar, wich have different innate resistance to stressful effect. Bol'. 2008:(2);13-6. (In Russ.)].

22. Акмаев ИГ, Гриневич ВВ. От нейроэндокринологии к нейроиммуноэндокринологии. Бюллетень экспериментальной биологии и медицины. 2001;(1):22-32. [Akmaev IG, Grinevich VV. From neuroendocrinology to neuroimmunoendocrinology. Byulleten' eksperimental'noi biologii i meditsiny. 2001;(1):22-32. (In Russ.)].

23. Шутов АА, Каракулова ЮВ, Батуева ЕА и др. Место серотонинергической системы в патогенезе хронических болевых синдромов. Пермский медицинский журнал. 2011;(6):5-10. [Shutov AA, Karakulova YuV, Batueva EA, et al. The place of the serotonergic system in the pathogenesis of chronic pain syndromes. Permskii meditsinskii zhurnal. 2011;(6):5-10. (In Russ.)].

24. Калюжный ЛВ. Физиологические механизмы регуляции болевой чувствительности. Москва: Медицина; 1984. 215 с. [Kalyuzhnyi LV. Fiziologicheskie mekhanizmy regulyatsii bolevoi chuvstvitel'nosti [Physiological mechanisms of regulation of pain sensitivity]. Moscow: Meditsina; 1984. 215 p.]

25. Котова МА, Пузин МН, Боднева СЛ и др. Исследование роли биологически активных соединений в формировании болевого синдрома при невралгии тройничного нерва и невропатии тройничного нерва. Клиническая неврология. 2010:(2);3-5. [Kotova MA, Puzin MN, Bodneva SL i dr. Investigation of the role of biologically active compounds in the formation of pain in trigeminal neuralgia. Klinicheskaya nevrologiya. 2010:(2);3-5. (In Russ.)].

26. Defrin R, Shramm L, Eli I. Gender role expectations of pain is associated with pain tolerance limit but not with pain threshold. Pain. 2009 Sep;145(1-2):230-6. doi: 10.1016/j.pain. 2009.06.028. Epub 2009 Jul 16.

27. Palmeira CC, Ashmawi HA, PossoIde P. Sex and pain perception and analgesia. Rev Bras Anestesiol. 2011 Nov-Dec;61(6):814-28. doi: 10.1016/S0034-7094(11)70091-5.

28. Тюзиков ИА. Эндокринологические аспекты патогенеза и фармакотерапии синдрома хронической урогенитальной неин- фекционной боли у женщин. Эффективная фармакотерапия. Эндокринология. 2014;1(9):4-16. [Tyuzikov IA. Endocrinological aspects of pathogenesis and pharmacotherapy of chronic noninfectious urogenital pain syndrome in women. Effektivnaya farmakoterapiya. Endokrinologiya. 2014;1(9):4-16. (In Russ.)].

29. Kaneyama S, Nishida K, Takada T, et al. Fas ligand expression on human nucleus pulposus cells decreases with disc degeneration processes. J Orthop Sci. 2008 Mar;13(2):130-5 DOI: 10.1007/s00776-007-1204-4

30. Takada T, Nishida K, Doita M, Kurosaka M. Fas ligand exists on intervertebral disc cells: a potential molecular mechanism for immune privilege of the disc. Spine (Phila Pa 1976). 2002 Jul 15;27(14):1526-30. DOI: 10.1002/jor.22274

31. Hernangоmez M, Klusаkovа I, Joukal M, et al. CD200R1 agonist attenuates glial activation, inflammatory reactions, and hypersensitivity immediately after its intrathecal application in a rat neuropathic pain model. J Neuroinflammation. 2016 Feb 18;13:43. doi: 10.1186/s12974-016-0508-8.

32. Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nat Rev Neurosci. 2005 Jul;6(7):521-32.

33. Walker DG, Dalsing-Hernandez JE, Campbell NA, Lue LF. Decreased expression of CD200 and CD200 receptor in Alzheimer's disease: a potential mechanism leading to chronic inflammation. Exp Neurol. 2009 Jan;215(1):5-19. doi: 10.1016/j.expneurol.2008.09.003. Epub 2008 Sep 24.


For citation:


Vyshlova I.A., Karpov S.M., Starodubtsev A.I. Neuroimmunological mechanisms of chronic pain syndrome. Neurology, Neuropsychiatry, Psychosomatics. 2016;8(2):113-116. (In Russ.) https://doi.org/10.14412/2074-2711-2016-2-113-116

Views: 352


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)